RARE SuperRare : Bullish and Bearish Analyst Opinions

Jeffrey mentions that for his son's disease (CTD), pharmaceutical companies are looking at "ASO therapy" (Antisense Oligonucleotide) and "prodrugs" to bypass the blood-brain barrier. Ionis (IONS) is the market leader in RNA-targeted ASO therapies, and Ultragenyx (RARE) specializes in rare genetic diseases and metabolic disorders. When a specific modality like ASO is highlighted as the solution for neurological transport issues, it validates the broader technology platforms of these specialized firms. Watch these tickers as proxies for advancements in ASO and rare disease drug delivery. Clinical trial failures are common in rare disease; "science is slow" (as stated by the guest).